COMPARISON OF HEALTHCARE COSTS FOR WOMEN WITH TREATED VS UNTREATED VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

被引：0
|
作者：
Shiozawa, A. [1 ]
Mancuso, S. [1 ]
Young, C. [1 ]
Friderici, J. [2 ]
Tran, S. [3 ]
Trenz, H. [3 ]
机构：
[1] Astellas Pharma Inc, Northbrook, IL USA
[2] Optum, Cape Coral, FL USA
[3] Optum, Eden Prairie, MN USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD61
引用
收藏
页码：S371 / S372
页数：2
相关论文
共 50 条
  • [41] TOLERABILITY OF DESVENLAFAXINE 100 MG IN WOMEN WITH VASOMOTOR SYMPTOMS (VMS) ASSOCIATED WITH MENOPAUSE: A POOLED ANALYSIS OF 5 TRIALS
    Archer, D. F.
    Shifren, J. L.
    Cheng, R. -F. J.
    Bao, W.
    Guico-Pabia, C. J.
    FERTILITY AND STERILITY, 2011, 96 (03) : S4 - S5
  • [42] A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative
    Lensen, Sarah
    Archer, David
    Bell, Robin J.
    Carpenter, Janet S.
    Christmas, Monica
    Davis, Susan R.
    Giblin, Karen
    Goldstein, Steven R.
    Hillard, Tim
    Hunter, Myra S.
    Iliodromiti, Stamatina
    Jaisamrarn, Unnop
    Joffe, Hadine
    Khandelwal, Sunila
    Kiesel, Ludwig
    Kim, Bobae V.
    Lambalk, Cornelis B.
    Lumsden, Mary Ann
    Maki, Pauline M.
    Nappi, Rossella E.
    Panay, Nick
    Roberts, Helen
    Shifren, Jan
    Simon, James A.
    Vincent, Amanda
    Wolfman, Wendy
    Hickey, Martha
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2021, 28 (08): : 852 - 858
  • [43] Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan
    Takamatsu, Kiyoshi
    Miki, Takashi
    Miyazaki, Kentaro
    Hashimoto, Atsuki
    He, Weizhong
    Wang, Xuegong
    CLIMACTERIC, 2024, 27 (04) : 389 - 397
  • [44] Pregabalin use for the management of menopause-associated vasomotor symptoms, a new alternative?
    Belardo, Maria A.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (12): : 1459 - 1460
  • [45] Efficacy of Paroxetine (7.5 mg) in the treatment of menopause-associated vasomotor symptoms
    Belardo, Maria A.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (12): : 1459 - 1459
  • [46] Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause
    Santoro, Nanette
    Johnson, Kimball
    Nappi, Rossella E.
    Neal-Perry, Genevieve
    Shapiro, Marla
    Stute, Petra
    Thurston, Rebecca C.
    Wolfman, Wendy
    English, Marci
    Franklin, Catherine
    Lee, Misun
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 154 - 155
  • [47] Qualitative Study of the Burden of Vasomotor Symptoms Associated With Menopause and Content Validity of Two PROMIS Sleep Measures in Menopausal Women
    English, Marci
    Stoykova, Boyka
    Slota, Christina
    Doward, Lynda
    Siddiqui, Emad
    Crawford, Rebecca
    DiBenedetti, Dana
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2020, 27 (12): : 1464 - 1464
  • [48] Vasomotor Symptoms and Menopause: Findings from the Study of Women's Health across the Nation
    Thurston, Rebecca C.
    Joffe, Nadine
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2011, 38 (03) : 489 - +
  • [49] Association Between Severity of Vasomotor Symptoms of Menopause and Work Productivity in a Survey of US Women
    DePree, Barbara
    Shiozawa, Aki
    King, Deanna
    Schild, Arianne
    Zhou, Mo
    Yang, Hongbo
    Mancuso, Shayna
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (12): : 1465 - 1465
  • [50] FPIN's Help Desk Answers SSRIs vs. SNRIs for Vasomotor Symptoms of Menopause
    Newhouser, Laura Morton
    Maneval, Mandy
    Rayalam, Kiran
    Sabeeh, Ghazala
    Varela, Lionel
    AMERICAN FAMILY PHYSICIAN, 2022, 105 (04) : 430 - 431
12345